HIV-1 protease is an essential enzyme in the life cycle of the HIV-1 virus. The conformational
dynamics of the flap region of the protease is critical for the ligand binding mechanism, as …

HIV-1 protease remains an important anti-AIDS drug target. Although it has been known that
ligand binding induces large conformational changes in the protease, the dynamic aspects …

A major problem in the antiretroviral treatment of HIV-infections with protease-inhibitors is
the emergence of resistance, resulting from the occurrence of distinct mutations within the …

The emergence of drug-resistant mutants of HIV-1 is a tragic effect associated with
conventional long-treatment therapies against acquired immunodeficiency syndrome. These …

The protease from type 1 human immunodeficiency virus (HIV‐1) is a critical drug target
against which many therapeutically useful inhibitors have been developed; however, the set …

Human immunodeficiency virus-1 (HIV-1) protease is an important drug target for acquired
immune deficiency syndrome therapy. Nearly 10 small molecule drugs have been approved …

A prominent characteristic of human immunodeficiency virus type 1 (HIV-1) is its high
genetic variability, which generates diversity of the virus and often causes a serious problem …

The emergence of compensatory drug-resistant mutations in HIV-1 protease challenges the
common view of the reaction mechanism of this enzyme. Here, we address this issue by …

A recent crystal structure of HIV‐1 protease (HIVp) was the first to experimentally observe a
ligand targeting an open‐flap conformation. Researchers studying a symmetric pyrrolidine …

Two different structures of ligand‐free HIV protease have been determined by X‐ray
crystallography. These structures differ in the position of two 12 residue, β‐hairpin regions …